hilar cholangiocarcinoma
Conditions
Interventions
experimental group:Radiofrequency ablation + biliary stent implantation + immunotherapy
control group:Radiofrequency ablation + biliary stent implantation
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. CT and MRI diagnosis should be confirmed by pathology or histology as far as possible; 3. Clinical jaundice, bilirubin > 5mg/dL, with or without cholangitis; 4. Patients with local macrovascular infiltration or distant metastasis indicated by color ultrasound, CT or MRI, and who could not be surgically removed or refused to be surgically removed after discussion by the expert group; 5. Those who have been diagnosed for the first time; 6. Patients willing to undergo endoscopic combined immunotherapy and long-term follow-up.
Exclusion criteria
Exclusion criteria: 1. Severe biliary tract infection; 2. Severe cardiopulmonary diseases, unable to tolerate surgery; 3. Patients with other malignant tumors; 4. Severe liver dysfunction (prothrombin time 442umol/L); 5. Other treatments that may affect the follow-up results: seed stent implantation, chemoradiotherapy, etc.Refusal of endoscopic therapy or withdrawal during immunotherapy; 6. Benign and malignant tumors of the pancreas, biliary tract and duodenum; 7. Failure in surgery; 8. Participate in other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| median overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| KPS score changes;Stent patency time;progression free survival time;adverse effects;death reasons; | — |
Countries
China
Contacts
Public ContactWu Qiao
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed